L.A. Times B2B Publishing’s Post

Publication Alert 📣 Our latest paper investigating the surgical treatment work-up of #gastric and #esophageal #cancer in Denmark by Astrid Kolind Christensen et.al. is out: https://lnkd.in/dD67Tepr Key Findings: * >950 patients were analyzed, undergoing both initial and specialized endoscopies prior to surgery. * 68% of initial endoscopies lacked sufficient preoperative tumor information. * In 12% of cases, findings from specialized endoscopies led to significant changes in surgical strategy. * Repeated endoscopy at specialized centers was identified as a critical factor in ensuring proper surgical treatment. This research underscores the importance of centralized care and specialized expertise in the treatment of #gastroesophageal cancer.

Endeavor Health is at the forefront of transforming breast cancer surgery with a pioneering clinical trial at Evanston Hospital. Led by Dr. Katherine Kopkash, Director of Oncoplastic Breast Surgery, this trial is exploring the potential of robotic-assisted, single-incision surgery for nipple-sparing mastectomies combined with immediate reconstruction—a promising advancement that could redefine patient care in breast cancer surgery 🔬 Learn more about this transformative study: https://bit.ly/3IKT2uA

Endometrial Cancer? Fear Not! Read How This 80-Year-Old Found Hope with Robotic Surgery at Sheikh Shakhbout Medical City - SSMC Mathebele Makwela, obstetrics and #gynecology consultant at #ssmc , explained: “Our approach throughout this case was to minimize any risks to the patient by adopting minimally invasive and highly accurate procedures. The patient is of an advanced age. Additionally, the patient suffers from clinically severe obesity. This condition adds to the risk associated with treating the cancer. However, the sentinel lymph node biopsy helped us accurately assess the cancer’s spread without subjecting the patient to the potential complications associated with traditional lymphadenectomy. Our robot-assisted hysterectomy further ensured thorough removal of affected tissue. And she was able to be discharged just two days after surgery.” Read More: https://lnkd.in/dNmQ-QYS #mededgemea #ssmc #roboticsurgery #surgery #cancer #endometrialcancer

Gastric Cancer Surgery: Balancing Oncological Efficacy against Postoperative Morbidity and Function Detriment Significant progress has been made in the surgical management of gastric cancer over the years, and previous discrepancies in surgical practice between different parts of the world have gradually lessened. A transition from the earlier period of progressively more extensive surgery to the current trend of a more tailored and evidence-based approach is clear. Prophylactic resection of adjacent anatomical structures or neighboring organs and extensive lymph node dissections that were once assumed to increase the chances of long-term survival are now performed selectively. Laparoscopic gastrectomy has been widely adopted and its indications have steadily expanded, from early cancers located in the distal part of the stomach, to locally advanced tumors where total gastrectomy is required. In parallel, function-preserving surgery has also evolved and now constitutes a valid option for early gastric cancer. Pylorus-preserving and proximal gastrectomy have improved the postoperative quality of life of patients, and sentinel node navigation surgery is being explored as the next step in the process of further refining the minimally invasive concept. Moreover, innovative techniques such as indocyanine green fluorescence imaging and robot-assisted gastrectomy are being introduced in clinical practice. These technologies hold promise for enhancing surgical precision, ultimately improving the oncological and functional outcomes. https://lnkd.in/ew425Ksi #ICG #indocyaninegreen #fluorescence #fluorescent #guidedsurgery #surgery #surgeon #imaging #thinkgreen #patients #safety #surgical #laparoscopic #cancer #gastric

A meningioma is a primary central nervous system (CNS) tumor. This means it begins in the brain or spinal cord. Overall, meningiomas are the most common type of primary brain tumor. However, higher grade meningiomas are very rare. To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, will be sent for histopathology and if required Immunohistochemistry evaluation. What Are the Grades of Meningiomas? Meningiomas are grouped into three grades based on their characteristics. Each grade (1, 2, or 3, also written as I, II, or III) includes different meningioma subtypes. Grade 1: meningiomas are the most common meningiomas. They are low grade tumors, which means the tumor cells grow slowly. Grade 2 : atypical meningiomas are mid-grade tumors. This means they have a higher chance of coming back after they’ve been removed. Grade 2 meningioma subtypes include chordoid and clear cell meningiomas. Grade 3 : anaplastic meningiomas are malignant (cancerous). This means they are fast-growing tumors. Grade 3 meningioma subtypes include papillary and rhabdoid meningiomas. Sharing experience Of Right Convexity Meningioma Microscopic Surgery adjacent to Motor Cortex( Histopathology Grade I ) . Post operative No Neurological deficit.

Hot topic in upper GI surgery! There is no conference without discussions on the extend of lymph node dissection in esophageal cancer surgery. Even when we can reach consensus on the extend, its anatomical boundaries and clearance of the adjacent structures vary between centers. #esophagectomy #Radboudumc #Amsterdamumc

Women over 50 can safely reduce mammogram frequency after breast cancer surgery https://ow.ly/nN9x50Qh0Vx #mammographyage #screeningmammography #mammography #breastcancer

📃Scientific paper: Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report Abstract: Background Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. Case presentation We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. Conclusions This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression. Continued on ES/IODE ➡️ https://etcse.fr/7Axbm ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report Abstract: Background Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. Case presentation We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. Conclusions This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression. Continued on ES/IODE ➡️ https://etcse.fr/7Axbm ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Exciting new research on #CAR-T cell gel and its potential to kill residual cancer cells left after surgery. Learn more in this article from Fierce Biotech. #CancerResearch #Immunotherapy #Surgery